Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 29, 2015 6:59 AM ET

Pharmaceuticals

Company Overview of AC Immune SA

Company Overview

AC Immune SA, a biopharmaceutical company, develops vaccines, antibodies, and small molecules for conformational diseases and cancer. The company develops active and passive immunotherapies against Alzheimer's disease using its molecular technology platform. It offers ACI-24, an Alzheimer's disease vaccine, which is designed to act as an active vaccine stimulating the patient's immune system to produce beta-sheet conformation-specific antibodies that prevent plaque deposition or enhance clearance of plaques; ACI-01-Ab7, a monoclonal antibody and passive immunotherapy; and Morphomers and ACI-91, the small molecules products. AC Immune SA was founded in 2003 and is based in Lausanne, Switzerla...

PSE Building B - EPFL

Lausanne,  1015

Switzerland

Founded in 2003

Phone:

41 21 693 91 21

Fax:

41 21 693 91 20

Key Executives for AC Immune SA

Co-Founder and Chief Executive Officer
Co-Founder and Member of the Scientific Advisory Board
Co-Founder
Chief Financial Officer
Chief Medical Officer
Compensation as of Fiscal Year 2014.

AC Immune SA Key Developments

AC Immune (Switzerland) Enter into an Exclusive Global License and Research Agreement with Janssen Pharmaceuticals

AC Immune (Switzerland) has entered into an exclusive global license and research agreement with Janssen Pharmaceuticals, which is focused on the development and commercialization of anti-Tau therapeutic vaccines for the treatment of Alzheimer's disease and other tauopathies, such as frontotemporal dementia, progressive supranuclear palsy, and amyotrophic lateral sclerosis. Based on the terms of the transaction, AC Immune will receive an upfront payment, as well as potential research, development, and commercialization milestone payments worth up to CHF 500 million (USD 509 million). Janssen will be responsible for the development of AC Immune's lead therapeutic vaccine, ACI-35, following the Phase Ib completion for Alzheimer's disease, as well as a potential second indication outside of the disease. Janssen will also be responsible for manufacturing and commercialization of ACI-35. The agreement also involved a three-year co-research collaboration for the potential characterization and development of novel vaccines for tauopathies. AC Immune will be eligible for tiered royalties on net sales from products resulting from the collaboration.

AC Immune SA Enters into a Worldwide Exclusive License Agreement and Research Collaboration with Janssen Pharmaceuticals, Inc

AC Immune SA has entered into a worldwide exclusive license agreement and research collaboration with Janssen Pharmaceuticals, Inc. to develop and commercialize therapeutic anti-tau vaccines for the treatment of Alzheimer's disease and potentially other tauopathies. Janssen Research & Development, LLC will further develop the lead therapeutic vaccine, ACI-35, that is currently in a phase Ib clinical trial in Alzheimer's patients. ACI-35 is a therapeutic vaccine stimulating the patient's immune system to produce a polyclonal antibody response against phosphorylated tau protein. Under the terms of the agreement, AC Immune will receive an upfront payment and is eligible to receive research, development and commercialization milestone payments potentially totaling up to $509 million for Alzheimer's disease and a potential second indication outside of Alzheimer's disease. Additionally, AC Immune is eligible to receive tiered royalties on net sales for any approved products resulting from the collaboration. AC Immune and Janssen will co-develop ACI-35 through phase Ib completion. As of phase II and onward, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of ACI-35. Additionally, AC Immune and Janssen Pharmaceuticals have entered a three year joint research collaboration to further characterize and develop novel vaccine therapies for the treatment of tauopathies.

AC Immune SA and Piramal Imaging Announce Out-Licensing Agreement for the Development of Tau Protein Diagnostics in Alzheimer's Disease

AC Immune SA and Piramal Imaging entered into an exclusive worldwide license agreement for the research, development and commercialization of AC Immune's Tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of Alzheimer's disease (AD) and potential Tau-related disorders. The formation of Tau tangles in the human brain is recognized as one of two major hallmarks of Alzheimer's disease pathology, with the other being beta-amyloid plaques. The development of the Tau tangle pathology appears to correlate well with cognitive decline, making it a potential strong target for diagnostic approaches. The availability of a Tau-PET tracer for imaging Tau tangles in the brain of patients would represent important progress towards relevant diagnostic endpoints and could be of significant value in guiding clinical trials for disease modifying AD therapeutics. Under the terms of the agreement, AC Immune will receive an undisclosed upfront payment and is eligible for significant milestone payments on products achieving development goals in AD and other Tauopathies. Additionally, AC Immune is entitled to receive tiered royalties on net sales of products resulting from the partnership. AC Immune will work in collaboration with Piramal Imaging to efficiently advance several lead candidates through late pre-clinical radio-pharmacology development. Piramal Imaging will have global rights for clinical development, manufacturing and commercialization of a Tau-PET Tracer resulting from the collaboration. Financial details were not disclosed. The agreement between the two companies is based on a long-term relationship in which AC Immune has used Piramal Imaging's beta-amyloid PET Tracer Neuraceq(TM) for imaging beta-amyloid plaques in the brain of patients undergoing Phase I/IIa clinical testing of AC Immune's Alzheimer's vaccine ACI-24. Neuraceq(TM) received marketing authorization from the FDA on March 19, 2014 for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline. Safety and effectiveness of Neuraceq(TM) have not been established for monitoring responses to therapies. Neuraceq(TM) received similar approval by the EC four weeks earlier.

Similar Private Companies By Industry

Company Name Region
PIQUR Therapeutics AG Europe
Clinuvel AG Europe
Novartis Pharma Schweiz AG Europe
NBE-Therapeutics GmbH Europe
Robapharm Sa Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AC Immune SA, please visit www.acimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.